<DOC>
	<DOCNO>NCT03066089</DOCNO>
	<brief_summary>This study open label , two arm trial evaluate safety efficacy Fenfuro capsule twice daily 90 day 100 patient type 2 diabetes conduct single center India . The primary outcome measure determination decrease plasma glucose level baseline last visit . The secondary outcome determination safety Fenfuro capsule type 2 diabetic subject .</brief_summary>
	<brief_title>Clinical Evaluation Fenfuro ( Fenugreek Seed Extract ) Type-2 Diabetic Subjects : add-on Study</brief_title>
	<detailed_description>Diabetes mellitus , involve rise blood sugar level , show highly prevalent disease . Treatments treatment regimen include combination oral anti-diabetic drug ( OADs ) , anti-hypertensive medication anti-dyslipidemic agent , less successful manage respective disease target clinical goal . Now-a-days , treatment strategy diabetes mellitus type 2 opt general population include natural supplement . This choice base upon involvement less side effect along high effectiveness natural supplement compare synthetic medication . One natural supplement fenugreek seed extract i.e . Fenfuro use nutraceutical present study management type 2 diabetes mellitus . Fenugreek extensively use source anti-diabetic compound long time . Thus , Fenfuro , prepare fenugreek seed extract , suppose anti-diabetic property well . Previous study fenugreek seed extract show effective safe anti-diabetic anti-hyperlipidemic property . It show decrease blood glucose level well lipid profile diabetic patient . In proposed study , Fenugreek seed extract use add-on exist therapy patient type-2 diabetes . The efficacy safety extract evaluate use standard methodology .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Fenugreek seed meal</mesh_term>
	<criteria>Agrees write well audiovisual inform consent . Patients either sex . Aged 1865 year . Fasting plasma glucose level &lt; 180 mg/dL . HbA1c level 7.5 % . Not receive steroid . Patient antidiabetic therapy . Uncooperative Subjects . Diabetes type2 diabetes mellitus . Evidence renal &amp; liver disease . History hemoglobinopathy may affect determination HbA1c . Lactating Pregnant plan conceive female . Physically/ mentally unwell certified physicianincharge . Participation clinical trial last 30 day . Subjects allergy investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FBS , HbA1C , PPBS</keyword>
</DOC>